Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Completed Study DFA102, including all procedures required at the Study Termination visit, without major protocol deviations~* Male, or female and meets all the following criteria:~  1. Has a negative urine pregnancy test result at Study start(not applicable to hysterectomized females)~ 2. If of childbearing potential must practice and be willing to continue to practice appropriate birth control during the entire duration of the study~* Able to read, understand, and sign the Informed Consent Form (ICF) and if applicable,an Authorization to Use and Disclose Protected Health Information Form, answer the study questionnaires, communicate with the investigator, and understand and comply with protocol requirements~Exclusion Criteria:~* Is expected to require or undergo treatment with any exclusionary medication.~* Is undesirable as a study participant as judged by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): Pramlintide and 1.25mg Metreleptin
- 3 (Type: EXPERIMENTAL): Pramlintide and 2.5mg Metreleptin
- 4 (Type: EXPERIMENTAL): Pramlintide and 5.0mg Metreleptin

Based on this trial design, predict the completion outcome and termination type (if applicable).